Pharmaceutical manufacturers have been keen to invest in drugs that have potential in multiple diseases, paving the way for revenue growth through indication expansion. The phrase “pipeline-in-a-pill” has become as ubiquitous in R&D circles as “string of pearls” has become in dealmaking.
An analysis of industry’s top-selling drugs underscores the value of indication expansion to drive growth, but also raises questions about...